scholarly journals Increased Risk of Second Primary Malignancy in Pediatric and Young Adult Patients Treated with Radioactive Iodine for Differentiated Thyroid Cancer

Thyroid ◽  
2015 ◽  
Vol 25 (6) ◽  
pp. 681-687 ◽  
Author(s):  
Jennifer L. Marti ◽  
Kunal S. Jain ◽  
Luc G.T. Morris
Keyword(s):  
Thyroid Cancer ◽  
Young Adult ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Adult Patients ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Increased Risk

scholarly journals Risk of Second Primary Malignancy in Patients Treated with Radioactive Iodine for Thyroid Cancer

2021 ◽  
Author(s):  
K McNamara ◽  
Veronica Barry ◽  
Alexander Yao ◽  
Joanne Weekes ◽  
Thomas Saunders ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Total Thyroidectomy ◽  
Neck Dissection ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Recurrence Rates ◽  
Primary Malignancy ◽  
Increased Risk

ABSTRACT Introduction Radioactive iodine (RAI) is widely used as a treatment for differentiated thyroid cancer following total thyroidectomy. There is a risk of second primary malignancy (SPM) in these patients which is estimated between 0-5% although research to support this is limited. The primary aim of this study was to ascertain the rate of SPM in patients who have undergone RAIT for thyroid cancer. The secondary objectives were to assess whether the risk is dose dependant and examine the overall survival and recurrence rates. Methods A retrospective review of all patients treated with radioactive iodine for thyroid cancer between 2002 and 2014. Patient information was collected from a structured database. Data regarding second cancers and recurrence rates was obtained from an online clinical portal. Follow up was 5 years minimum. Results 199 patients underwent RAI treatment. Median age was 53. 71.4% patients were female and 28.6% were male. All patients underwent total thyroidectomy. 13.6% underwent total thyroid and central neck dissection. 11% underwent total thyroidectomy and lateral neck dissection. 5.5% required post-operative radiotherapy. 12% patients developed recurrent thyroid cancer. 8% developed a SPM of which prostate, skin, head and neck SCC were the most common. A dose ≥3.7 (Gigabecquerel) GBq was statistically significantly more likely to lead to a SPM with a P value of 0.041 (95% CI -0.52 – 0.01318). Conclusions Increased risk of developing a second primary malignancy should be taken into account, especially in younger patients with low risk disease, when deciding on RAIT. Key words Radioactive iodine, Differentiated thyroid cancer, Second primary malignancy, Radioiodine, Thyroid cancer

scholarly journals Is radioactive iodine- 131 treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer?

2016 ◽  
Vol 60 (1) ◽  
pp. 9-15 ◽  
Author(s):  
Marcelo Cruzick de Souza ◽  
Denise P. Momesso ◽  
Fernanda Vaisman ◽  
Leonardo Vieira Neto ◽  
Rosangela Aparecida Gomes Martins ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Iodine 131 ◽  
Radioactive Iodine 131

scholarly journals Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis

Thyroid ◽  
2009 ◽  
Vol 19 (5) ◽  
pp. 451-457 ◽  
Author(s):  
Anna M. Sawka ◽  
Lehana Thabane ◽  
Luciana Parlea ◽  
Irada Ibrahim-Zada ◽  
Richard W. Tsang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Thyroid Cancer ◽  
Radioactive Iodine ◽  
Meta Analysis ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Malignancy Risk ◽  
Iodine Treatment

The risk of second primary cancers in clear cell and papillary renal cancer.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 446-446 ◽  
Author(s):  
Muhammad Saad Hamid ◽  
Raji Shameem ◽  
Rishi Jain ◽  
Kevin M. Sullivan
Keyword(s):  
Thyroid Cancer ◽  
Solid Tumors ◽  
Clear Cell ◽  
Latency Period ◽  
Initial Diagnosis ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Second Primary Cancers ◽  
Increased Risk

446 Background: Renal cell carcinoma (RCC) survivors have an increased risk of developing second primary cancers. We sought to determine the role of RCC tumor histology for the risk of developing second primary solid tumors. Methods: The Surveillance Epidemiology and End Results (SEER) database was used to detect RCC cases diagnosed up to 12/31/2011. The Standardized Incidence Ratio (SIR) was calculated as the ratio of observed to expected cases of second primary malignancy based on incidence data in the general United States population. The two most common RCC histological subtypes were included; clear cell and papillary. The latency exclusion period from the date of diagnosis was 60 months. We investigated for the effect of latency period after initial diagnosis (5-10 years and >10 years) that may increase the risk for a second primary cancer. Results: A total of 2,669 patients with an initial diagnosis of RCC (clear cell: 2,368, papillary: 301) that developed second primary cancers were included in our analysis. There was a significantly increased risk of thyroid cancer (SIR: 2.30, p<0.05), prostate cancer (SIR: 1.12, p<0.05) and “all solid tumors” (SIR: 1.14, p<0.05) in clear cell RCC cases. Regarding latency period, thyroid cancer (SIR: 2.87, p<0.05) risk was increased in the 5-10 years latency period, but not in the >10 years latency period. Overall, in patients diagnosed with papillary RCC, tumors of the prostate (SIR: 1.30, p<0.05), lung (SIR: 1.78, p<0.05) and pancreas (SIR: 2.70, p<0.05) were increased. Exclusively in the 5-10 years latency period, the risk for developing lung cancer (SIR: 1.90, p<0.05) was significant. Conclusions: RCC histology may impact the risk for developing specific second primary solid tumors.

The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative131I dose over 37 GBq

2014 ◽  
Vol 83 (1) ◽  
pp. 117-123 ◽  
Author(s):  
Ah Reum Khang ◽  
Sun Wook Cho ◽  
Hoon Sung Choi ◽  
Hwa Young Ahn ◽  
Won Sang Yoo ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Differentiated Thyroid Cancer ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy

scholarly journals Incidence of Second Malignancy in Patients with Papillary Thyroid Cancer from Surveillance, Epidemiology, and End Results 13 Dataset

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Mayumi Endo ◽  
Jessica B. Liu ◽  
Marcelle Dougan ◽  
Jennifer S. Lee
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Incidence Rates ◽  
Lymphocytic Leukemia ◽  
Second Primary ◽  
Papillary Thyroid ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Increased Risk ◽  
End Results

Increased risk of second primary malignancy (SPM) in papillary thyroid cancer (PTC) has been reported. Here, we present the most updated incidence rates of second primary malignancy from original diagnosis of PTC by using the data from the Surveillance, Epidemiology, and End Results. In this cohort, 3,200 patients developed SPM, a substantially higher number than in the reference population of 2,749 with observed to expected ratio (O/E) of 1.16 (95% CI; 1.12–1.21). Bone and joint cancer had the highest O/E ratio of 4.26 (95% confidence interval [CI] 2.33–7.15) followed by salivary gland (O/E 4.15; 95% CI 2.76–6.0) and acute lymphocytic leukemia (O/E 3.98; 95% CI 2.12–6.8). Mean age at the diagnosis of SPM was 64.4 years old. Interestingly, incidence of colorectal cancer was lower in thyroid cancer survivors compared to general population (large intestine O/E 0.3; 95% CI 0.06–0.88, rectum O/E 0.6; 95% CI 0.41–0.85); however, this was not observed in patients who underwent radiation therapy. The incidence of SPM at all sites was higher during 2000–2012 compared to 1992–1999 (O/E 1.24 versus 1.10). Surprisingly, patients with micropapillary cancer had higher incidence of SPM than counterparts with a larger tumor in radiation group (O/E of 1.40 versus 1.15). O/E of all cancers were higher in males compared to females with O/E of 1.41 versus 1.17 during the period of 2000–2012. Diagnosis of PTC before age 50, especially at age 30–34, was associated with higher incidence of overall SPM (age 30–34; O/E 1.43; 95% CI; 1.19–1.71). Efficient monitoring strategies that include age at the time of thyroid cancer diagnosis, exposure to radiation, gender, and genetic susceptibility may successfully detect SPM earlier in the disease course. This is especially important given the excellent prognosis of the initial thyroid cancer itself.

scholarly journals Is there an increased risk of second primary malignancy after diagnosis of thyroid cancer?

Cancer ◽  
2014 ◽  
Vol 121 (2) ◽  
pp. 166-168 ◽  
Author(s):  
Aarti Mathur ◽  
Eric B. Schneider ◽  
Martha A. Zeiger
Keyword(s):  
Thyroid Cancer ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Increased Risk ◽  
Diagnosis Of Thyroid Cancer

Occurrence of second primary malignancy in medullary thyroid cancer (MTC) patients

2019 ◽  
Author(s):  
George Simeakis ◽  
Katerina Saltiki ◽  
Evangelia Zapanti ◽  
Evanthia Kassis ◽  
Maria Alevizaki
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Medullary Thyroid
Sign in / Sign up

Export Citation Format

Share Document